BACKGROUND Glioblastoma is a common and aggressive primary malignant brain tumour in adults associated with a poor prognosis and considerable symptom burden. Clinical review and serial neuroimaging remain the primary monitoring tools to assess for disease status. However, the evidence base for the existing surveillance imaging schedule is yet to be established. New models of follow up care are needed to demonstrate better patient outcomes in this patient cohort. There are indications that patient-reported outcome measures (PROMs) can contribute to improved survival and maintaining an optimal quality of life in other oncology populations. MATERIALS AND METHODS There are no standardised PROMs for the priority symptoms in glioblastoma patients, which can be used for evaluation in clinical care as a surrogate marker for disease progression. A broad set of symptoms were therefore initially identified in a targeted literature search and were further refined via Delphi methodology, with the aim to obtain consensus amongst a small expert panel involved in the care of glioblastoma patients. A three round Delphi email survey was conducted. Consensus was defined as 70% agreement. RESULTS Symptom and function constructs were assessed for relevance, relationship to disease and treatment, sensitivity to change, psychometric properties and patient acceptability. Consensus was reached on the red flag symptoms and symptom clusters to monitor, as well as the minimum severity thresholds needed to trigger an alert on an electronic symptom reporting system, which has been developed to allow patient self-reporting of symptoms during treatment. CONCLUSION The red flag symptoms to monitor, along with the symptom severity thresholds, informed an app-based symptom reporting system, which is currently being piloted in a feasibility study exploring triggered imaging using ePROMs. This has the potential to inform future clinical practice through development of patient reported biomarkers.

中文翻译：

---

P12.03 一项德尔福调查以告知电子患者的核心“危险信号”症状，报告胶质母细胞瘤随访结果系统

背景技术胶质母细胞瘤是成人中常见的侵袭性原发性恶性脑肿瘤，与预后不良和相当大的症状负担相关。临床审查和系列神经影像学仍然是评估疾病状态的主要监测工具。然而，现有监测成像计划的证据基础尚未建立。需要新的随访护理模型来证明该患者队列中更好的患者结果。有迹象表明，患者报告的结果测量 (PROM) 有助于提高其他肿瘤学人群的生存率和维持最佳生活质量。材料和方法 没有针对胶质母细胞瘤患者优先症状的标准化 PROM，可作为疾病进展的替代标志物用于临床护理评估。因此，最初在有针对性的文献搜索中确定了一系列广泛的症状，并通过 Delphi 方法进一步完善，目的是在参与胶质母细胞瘤患者护理的小型专家小组中达成共识。进行了三轮德尔福电子邮件调查。共识被定义为 70% 的同意。结果 对症状和功能结构的相关性、与疾病和治疗的关系、对变化的敏感性、心理测量特性和患者可接受性进行了评估。就需要监测的红旗症状和症状群以及触发电子症状报告系统警报所需的最低严重性阈值达成共识，该系统已开发用于允许患者在治疗期间自我报告症状。结论 要监测的红旗症状，除了症状严重程度阈值外，还通知了一个基于应用程序的症状报告系统，该系统目前正在一项探索使用 ePROM 触发成像的可行性研究中进行试点。这有可能通过开发患者报告的生物标志物来为未来的临床实践提供信息。